CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...8990919293949596979899...39323933»
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    Journal:  Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report. (Pubmed Central) -  Jul 21, 2024   
    We reported a patient with hepatocellular carcinoma (HCC) who received PD-1 inhibitor treatment before operation and successfully underwent ABOi LT. The present case report provides novel insights into the perioperative management of utilizing PD-1 inhibitors prior to ABOi LT in patients diagnosed with hepatocellular carcinoma (HCC).
  • ||||||||||  Nulojix (belatacept) / BMS
    Retrospective data, Journal:  Belatacept based immunosuppression: What and when to combine? (Pubmed Central) -  Jul 21, 2024   
    Further studies with longer follow-up and larger samples are warranted. The present study demonstrates comparable transplant outcomes in terms of eGFR, graft survival, incidence of infections and neoplasia, rejection rate and donor specific antibody (DSA) in three belatacept-based maintenance immunosuppression regimens supporting the safety and efficacy of these therapeutic options.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Pembrolizumab-induced Liver Injury: Beyond Immune-Mediated Hepatitis. (Pubmed Central) -  Jul 21, 2024   
    The present study demonstrates comparable transplant outcomes in terms of eGFR, graft survival, incidence of infections and neoplasia, rejection rate and donor specific antibody (DSA) in three belatacept-based maintenance immunosuppression regimens supporting the safety and efficacy of these therapeutic options. No abstract available
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Verzenio (abemaciclib) / Eli Lilly
    Journal:  The relevance of therapeutic positioning in the post-approval evaluation of new medicines. (Pubmed Central) -  Jul 21, 2024   
    Also, pembrolizumab is approved for neoadjuvant plus adjuvant treatment in lung cancer; but it remains to be analyzed whether it is superior to nivolumab in neoadjuvant treatment alone, which involves less treatment and economic burden...This allows policy makers to make the most appropriate decisions on pricing and funding new treatments. In an ideal situation, the benefit scenario considered for the new medicine would coincide with the one established for funding, but costs that are difficult to bear may lead to restrictions and affect the final positioning after the economic and budgetary impact assessment.
  • ||||||||||  volrustomig (MEDI5752) / AstraZeneca
    Review, Journal:  Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer. (Pubmed Central) -  Jul 21, 2024   
    Only some phase I results in such development is published so far and no full report on this is available till now. This effort will try to record the facts and chain of events which actually occurred in inventing and bringing it in phase III trial.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Checkpoint inhibition:  Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition. (Pubmed Central) -  Jul 20, 2024   
    Therefore, careful monitoring is recommended to detect non-response early in patients with skin metastases as skin metastases may have a worse response than TT. A larger cohort is needed for a comprehensive analysis and confirmation of our results.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche
    Retrospective data, Journal:  Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss. (Pubmed Central) -  Jul 20, 2024   
    The most commonly taken disease modifying therapy (DMT) was ocrelizumab (39%) while 24% of patients were not taking any DMT...Four patients accrued new demyelinating lesions on MRI (one on no DMT, two started on a high-efficacy DMT for the first time in the past 6 months, and one on a high-efficacy DMT) and one patient experienced a new MS attack (treated with interferon beta-1a). Our early experience suggests GLP-1 agonists are safe in MS patients, who have a similar tolerability to the general population on this medication class and measurable and sustained but somewhat less than anticipated weight loss.
  • ||||||||||  Orencia (abatacept) / BMS
    Journal:  Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation. (Pubmed Central) -  Jul 19, 2024   
    Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first FDA-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT)...Primary outcomes included day-180, 1-year, and 2-year overall survival (OS) and relapse-free survival (RFS) for abatacept+CNI/MTX vs CNI/MTX, CNI/MTX+antithymocyte globulin (ATG), and post-transplant cyclophosphamide-based prophylaxis (PT-Cy); other outcomes included aGVHD, chronic GVHD, non-relapse mortality, and relapse...For both 7/8-MMUD and 8/8-MUD recipients, abatacept+CNI/MTX prophylaxis improved survival outcomes vs CNI/MTX and CNI/MTX+ATG; outcomes were similar to PT-Cy-based regimens. Abatacept+CNI/MTX has potential to facilitate unrelated donor pool expansion for HCT.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
    Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  The role of immunotherapy in early-stage and metastatic NSCLC. (Pubmed Central) -  Jul 19, 2024   
    Based on the benefit of disease-free survival, the approval of adjuvant atezolizumab and adjuvant pembrolizumab was a significant breakthrough. In the metastatic setting, the use of immune checkpoint inhibitors with chemotherapy, regardless of PD-L1 expression or ICI alone (PD-L1 expression equal to or greater than 50%) also improves overall survival and progression-free survival.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Review, Journal, IO biomarker:  All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia. (Pubmed Central) -  Jul 19, 2024   
    ATRA can also increase the expression of CD38 expressed by tumor cells, thus improving the efficacy of daratumumab and CD38-CART. In this review, we focus on the mechanism of action of ATRA, its role in various hematologic diseases, drug combinations, and ongoing clinical trials.
  • ||||||||||  Jemperli (dostarlimab-gxly) / GSK
    Review, Journal, Mismatch repair, Metastases:  Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer. (Pubmed Central) -  Jul 19, 2024   
    P1
    In conclusion, dostarlimab is an immunotherapy-based drug that has shown promising results in adult patients with recurrent or advanced dMMR EC. However, its efficacy in other cancer subtypes, the development of resistance to monotherapy, and efficacy and safety in combination with other immunotherapeutic drugs have not yet been studied.
  • ||||||||||  Retrospective data, Review, Journal, Metastases:  Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review. (Pubmed Central) -  Jul 19, 2024   
    The only FDA approved immunotherapy medication for metastatic uveal melanoma is the HLA-A02:01 restricted bispecific T cell engager drug, Tebentafusp...Twenty-three (92%) patients received systemic therapy, 13 patients (52%) received ipilimumab-nivolumab as the first-line, while 4 patients (16%) received pembrolizumab...Within our cohort, there was no overall survival benefit for patients receiving treatment of metastatic disease within 6 months of mUM diagnosis, versus those electing later or no treatment at all. There was remarkable clinical activity of ipilimumab and nivolumab in a subset of patients with mUM, in agreement with prior studies, and metastatic PD-L1 positive tumors were associated with a prolonged survival.
  • ||||||||||  zamtocabtagene autoleucel (MB-CART2019.1) / Miltenyi Biotec
    Trial completion, Trial completion date:  Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (clinicaltrials.gov) -  Jul 19, 2024   
    P1/2,  N=12, Completed, 
    There was remarkable clinical activity of ipilimumab and nivolumab in a subset of patients with mUM, in agreement with prior studies, and metastatic PD-L1 positive tumors were associated with a prolonged survival. Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2024
  • ||||||||||  Opdivo (nivolumab) / BMS
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  VIGOR: Neoadjuvant Aliya (clinicaltrials.gov) -  Jul 19, 2024   
    P4,  N=5, Terminated, 
    Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Sep 2024 --> Jan 2024 N=15 --> 5 | Trial completion date: Jun 2024 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Feb 2024; Strategic
  • ||||||||||  VRC01 / Acuitas Therap
    Journal, IO biomarker:  HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy. (Pubmed Central) -  Jul 19, 2024   
    We also find that an emtricitabine-based antiretroviral drug regimen dramatically enhances the efficacy of VIT, by reducing the fitness of mutants along the escape path. Our findings demonstrate that bNAb escapability is a key determinant to consider in the rational design of antibody regimens with maximal efficacy and illustrates a tractable means of minimizing viral escape from existing bNAbs.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Journal, Checkpoint inhibition:  Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor. (Pubmed Central) -  Jul 19, 2024   
    The patient achieved a complete and durable response after receiving only two cycles of the immune checkpoint inhibitor Nivolumab...Moreover, the patient developed a highly uncommon subdiaphragmatic pararectal dissemination of the thymic tumor, which is a condition rarely described in the literature. Despite the success in achieving complete and durable response with immune checkpoint inhibitors, the emergence of immune-related adverse events highlights the potential challenges associated with these treatments, emphasizing the need for careful monitoring and a comprehensive understanding of the intricate interplay between cancer, immune system dysregulations and immunotherapy.